<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00853489</url>
  </required_header>
  <id_info>
    <org_study_id>W81XWH-09-20108</org_study_id>
    <secondary_id>15915</secondary_id>
    <nct_id>NCT00853489</nct_id>
  </id_info>
  <brief_title>rhBMP-2 Versus Autograft in Critical Size Tibial Defects</brief_title>
  <official_title>RhBMP-2 vs. Autograft for Critical Size Tibial Defects: A Multicenter Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Louis University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Major Extremity Trauma Research Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Louis University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of our study is to evaluate the use of recombinant human bone morphogenetic
      protein 2 (RhBMP-2) as compared to standard ICBG in the treatment of severe open tibia
      fractures with a critical size bone defect (at least one centimeter in length compromising at
      least 50% of the circumference of the bone).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open tibia fractures have a 15% or higher rate of not healing. Those fractures which do not
      heal are typically treated with bone from the hip (iliac crest autograft; or ICBG). The use
      of ICBG bone with the treatment of delayed unions/non-unions with critical defect, although
      successful, has its drawbacks. The bone graft sources are limited and the procedure is
      associated with additional operating room time plus a second incision with increased risk of
      infection, post operative pain and increased hospital stay. The purpose of this study is to
      determine if Rh-BMP2, a new bone graft substitute, is at least as effective as using bone
      from the hip (autograft) to help promote healing of open, tibia (shin bone) fractures.

      Research Questions:

      Primary:

      What is the relative effect of rhBMP-2 versus autogenous ICBG on rates of union in patients
      with critical size defects following tibial shaft fractures?

      Null hypothesis #1: rhBMP-2 has the same union rate when used in critical-sized defects as
      does ICBG.

      Secondary:

      What is the relative effect of rhBMP-2 versus autogenous ICBG on infection rates in patients
      with nonunion or critical size defects following tibial shaft fractures?

      Null hypothesis #2: The infection rate in open tibias with critical-sized defects treated
      with rhBMP-2 and autogenous ICBG are the same.

      What is the economic impact of the use of Rh-BMP 2 for tibial fractures with critical sized
      defects?

      Null hypothesis #3: There will be no difference in the economic cost of the treatment of
      critical sized defects using the RhBMP-2 versus iliac crest bone graft.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment too slow
  </why_stopped>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 17, 2017</completion_date>
  <primary_completion_date type="Actual">February 17, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fracture Healing (Union) at 12 Months</measure>
    <time_frame>12 months post op</time_frame>
    <description>Union will be defined by:
1. Radiographic union as defined by the Radiographic union scale in tibia fractures (RUST) score, Radiographic evaluation will be assessed by blinded orthopaedic surgeons.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infection</measure>
    <time_frame>12 months post op.</time_frame>
    <description>Infection will be assessed based on the CDC criteria for deep and superficial infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Cost</measure>
    <time_frame>12 mos post op</time_frame>
    <description>An economic evaluation will also be performed including the costs of iliac crest bone graft harvest and complications from the bone graft surgery and the cost of the Rh-BMP 2 and the biologic implant used in the treatment group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Tibial Fractures</condition>
  <arm_group>
    <arm_group_label>recombinant bone morphogenetic protein 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient will receive rhBMP-2 plus allograft chips in the bone defect site. Intervention type: surgical</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autogenous iliac crest bone graft</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bone will be harvested from the iliac crest and placed in the bone defect.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>recombinant bone morphogenetic protein 2</intervention_name>
    <description>Patients will receive 1.50 mg/ml -12 mg of rhBMP-2 soaked on a absorbable collagen sponge (rhBMP-2/ACS) as an adjuvant to a freeze-dried cancellous allograft</description>
    <arm_group_label>recombinant bone morphogenetic protein 2</arm_group_label>
    <other_name>(rhBMP-2) (INFUSE)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autogenous iliac crest bone graft</intervention_name>
    <description>Patients will undergo autogenous iliac crest bone graft surgery per the surgeon's usual practice.</description>
    <arm_group_label>Autogenous iliac crest bone graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18-65 years old with an open tibia fracture involving diaphysis (if patient
             has a bilateral tibia fracture and both require a bone graft, then each will be
             randomized separately).

          -  Tibia fractures with a circumferential bone defect of at least one centimeter in
             length compromising at least 50% of the circumference of the bone.

          -  The definitive treatment of the tibia fracture must be with an intramedullary nail
             (may have temporary external fixation prior to IM nail placement).

          -  Patients whose treatment plan includes placement of a bone graft between 6 to 16 weeks
             after their initial injury.

          -  Patients who have no evidence of infection by clinical examination (defined as active
             infection at the operative site, purulent drainage from the fracture or evidence of
             active osteomyelitis at the time of bone graft).

          -  Patients who are independent in living and ambulation prior to injury.

          -  Patients who are English speaking.

          -  Patients who are willing to provide consent and available for follow-up for at least
             12 months following definitive surgical procedure.

        Exclusion Criteria:

          -  Patients who are pregnant or lactating.

          -  Patients with known hypersensitivity to rhBMP-2 or bovine type I collagen.

          -  Patients with a history of tumor, a resected or extant tumor, an active malignancy, or
             patients undergoing treatment for malignancy.

          -  Patients who are skeletally immature (&lt;18 years of age or no radiographic evidence of
             epiphyseal closure).

          -  Patients with inadequate neurovascular status, e.g. high risk of amputation.

          -  Patients with compartment syndrome of the affected limb.

          -  Patients with immune deficiency or history of auto-immune disease,

          -  Patients who have undergone treatment of any other investigational therapy within the
             month preceding implantation or planned within the 12 months following implantation.

          -  Patients unable to return for required follow-up visits.

          -  Patients who have medical co-morbidities that preclude treatment with a general
             anesthetic.

          -  Patient who is pending incarceration or who is incarcerated.

          -  Patients with an active infection at the operative site, purulent drainage from the
             fracture or evidence of active osteomyelitis at the time of bone grafting.

          -  Patient has intraoperative positive gram stain or an elevated CRP after laboratory
             screening for infection.

          -  Patient has segmental defects longer than 5cm in length.

          -  Patients who have segmental defects that require more than 60 cc of bone graft.

          -  Patients who require more than one large kit of rhBMP-2 at time of surgery.

          -  Patient's anticipated treatment plan also includes the use of other procedures to
             promote fracture healing, e.g. ultrasound, magnetic field or electrical stimulation.

          -  Patient's tibia fracture has been treated with additional fixation beyond the
             intramedullary nail, e.g. plates, wires or screws.

          -  Patients who have pathological fractures; a known history of Paget's disease or known
             history of heterotropic calcification.

          -  Patients with a Glasgow Coma Scale less than 15 (less than fully awake) at the time of
             informed consent.

          -  Patients with previous hardware in place that prevents placement of an intramedullary
             nail for treatment of the tibial shaft fracture.

          -  Patients with prior use of INFUSE.

        If the patient is a female of child bearing potential:

          -  Does she have a negative pregnancy test (administered within 72 hours prior to
             surgery)?

          -  Has she agreed to use adequate contraception for a period of at least 1 year following
             implementation of rhBMP-2?
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Cannada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Louis Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Tornetta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Health and Hospital Authority</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Orthopaedic Institute / Tampa General &amp; St. Joseph's Hospitals</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma / OU Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234-6315</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington / Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104-2499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2009</study_first_submitted>
  <study_first_submitted_qc>February 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2009</study_first_posted>
  <results_first_submitted>February 14, 2018</results_first_submitted>
  <results_first_submitted_qc>February 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 13, 2018</results_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open tibia fractures</keyword>
  <keyword>rhBMP-2</keyword>
  <keyword>critical size defects</keyword>
  <keyword>bone grafting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tibial Fractures</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>34 consented One was inelgible at time of graft due to infection pre enrollment Two were outside study period One Administrative withdrawl Total randomized : 30</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Recombinant Bone Morphogenetic Protein 2</title>
          <description>The patient will receive rhBMP-2 plus allograft chips in the bone defect site. Intervention type: surgical
recombinant bone morphogenetic protein 2: Patients will receive 1.50 mg/ml -12 mg of rhBMP-2 soaked on a absorbable collagen sponge (rhBMP-2/ACS) as an adjuvant to a freeze-dried cancellous allograft</description>
        </group>
        <group group_id="P2">
          <title>Autogenous Iliac Crest Bone Graft</title>
          <description>Bone will be harvested from the iliac crest and placed in the bone defect.
Autogenous iliac crest bone graft: Patients will undergo autogenous iliac crest bone graft surgery per the surgeon's usual practice.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Recombinant Bone Morphogenetic Protein 2</title>
          <description>The patient will receive rhBMP-2 plus allograft chips in the bone defect site. Intervention type: surgical
recombinant bone morphogenetic protein 2: Patients will receive 1.50 mg/ml -12 mg of rhBMP-2 soaked on a absorbable collagen sponge (rhBMP-2/ACS) as an adjuvant to a freeze-dried cancellous allograft</description>
        </group>
        <group group_id="B2">
          <title>Autogenous Iliac Crest Bone Graft</title>
          <description>Bone will be harvested from the iliac crest and placed in the bone defect.
Autogenous iliac crest bone graft: Patients will undergo autogenous iliac crest bone graft surgery per the surgeon's usual practice.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" spread="12"/>
                    <measurement group_id="B2" value="35" spread="12"/>
                    <measurement group_id="B3" value="36" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Count of participants</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fracture Healing (Union) at 12 Months</title>
        <description>Union will be defined by:
1. Radiographic union as defined by the Radiographic union scale in tibia fractures (RUST) score, Radiographic evaluation will be assessed by blinded orthopaedic surgeons.</description>
        <time_frame>12 months post op</time_frame>
        <population>RUST scores were used to determine radiograpghic union at 52 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Bone Morphogenetic Protein 2</title>
            <description>The patient will receive rhBMP-2 plus allograft chips in the bone defect site. Intervention type: surgical
recombinant bone morphogenetic protein 2: Patients will receive 1.50 mg/ml -12 mg of rhBMP-2 soaked on a absorbable collagen sponge (rhBMP-2/ACS) as an adjuvant to a freeze-dried cancellous allograft</description>
          </group>
          <group group_id="O2">
            <title>Autogenous Iliac Crest Bone Graft</title>
            <description>Bone will be harvested from the iliac crest and placed in the bone defect.
Autogenous iliac crest bone graft: Patients will undergo autogenous iliac crest bone graft surgery per the surgeon's usual practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Fracture Healing (Union) at 12 Months</title>
          <description>Union will be defined by:
1. Radiographic union as defined by the Radiographic union scale in tibia fractures (RUST) score, Radiographic evaluation will be assessed by blinded orthopaedic surgeons.</description>
          <population>RUST scores were used to determine radiograpghic union at 52 weeks</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infection</title>
        <description>Infection will be assessed based on the CDC criteria for deep and superficial infection.</description>
        <time_frame>12 months post op.</time_frame>
        <population>Infection was decribed in protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Bone Morphogenetic Protein 2</title>
            <description>The patient will receive rhBMP-2 plus allograft chips in the bone defect site. Intervention type: surgical
recombinant bone morphogenetic protein 2: Patients will receive 1.50 mg/ml -12 mg of rhBMP-2 soaked on a absorbable collagen sponge (rhBMP-2/ACS) as an adjuvant to a freeze-dried cancellous allograft</description>
          </group>
          <group group_id="O2">
            <title>Autogenous Iliac Crest Bone Graft</title>
            <description>Bone will be harvested from the iliac crest and placed in the bone defect.
Autogenous iliac crest bone graft: Patients will undergo autogenous iliac crest bone graft surgery per the surgeon's usual practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Infection</title>
          <description>Infection will be assessed based on the CDC criteria for deep and superficial infection.</description>
          <population>Infection was decribed in protocol</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medical Cost</title>
        <description>An economic evaluation will also be performed including the costs of iliac crest bone graft harvest and complications from the bone graft surgery and the cost of the Rh-BMP 2 and the biologic implant used in the treatment group.</description>
        <time_frame>12 mos post op</time_frame>
        <population>Hospital bills for bone graft surgery admission were available on 25 patients total</population>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Bone Morphogenetic Protein 2</title>
            <description>The patient will receive rhBMP-2 plus allograft chips in the bone defect site. Intervention type: surgical
recombinant bone morphogenetic protein 2: Patients will receive 1.50 mg/ml -12 mg of rhBMP-2 soaked on a absorbable collagen sponge (rhBMP-2/ACS) as an adjuvant to a freeze-dried cancellous allograft</description>
          </group>
          <group group_id="O2">
            <title>Autogenous Iliac Crest Bone Graft</title>
            <description>Bone will be harvested from the iliac crest and placed in the bone defect.
Autogenous iliac crest bone graft: Patients will undergo autogenous iliac crest bone graft surgery per the surgeon's usual practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Medical Cost</title>
          <description>An economic evaluation will also be performed including the costs of iliac crest bone graft harvest and complications from the bone graft surgery and the cost of the Rh-BMP 2 and the biologic implant used in the treatment group.</description>
          <population>Hospital bills for bone graft surgery admission were available on 25 patients total</population>
          <units>dollars for total admission cost</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13033" lower_limit="9038" upper_limit="22041"/>
                    <measurement group_id="O2" value="7535" lower_limit="2480" upper_limit="22915"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>One year after enrollment</time_frame>
      <desc>The definition of adverse events/SAE does not differ from clinicaltrials.gov</desc>
      <group_list>
        <group group_id="E1">
          <title>Recombinant Bone Morphogenetic Protein 2</title>
          <description>The patient will receive rhBMP-2 plus allograft chips in the bone defect site. Intervention type: surgical
recombinant bone morphogenetic protein 2: Patients will receive 1.50 mg/ml -12 mg of rhBMP-2 soaked on a absorbable collagen sponge (rhBMP-2/ACS) as an adjuvant to a freeze-dried cancellous allograft</description>
        </group>
        <group group_id="E2">
          <title>Autogenous Iliac Crest Bone Graft</title>
          <description>Bone will be harvested from the iliac crest and placed in the bone defect.
Autogenous iliac crest bone graft: Patients will undergo autogenous iliac crest bone graft surgery per the surgeon's usual practice.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Infection definition described in protocol</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Non union</sub_title>
                <description>Defined in protocol</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Lisa Kaye Cannada</name_or_title>
      <organization>Saint Louis University</organization>
      <phone>3145778850 ext 7</phone>
      <email>LCannada@slu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

